狂犬病疫苗市場 - 按產品類型 [嬰兒倉鼠腎 (BHK)、Vero 細胞狂犬病疫苗]、類型（人用、獸用）、應用（暴露前預防、暴露後預防）、配銷通路、全球預測（2024 年- 2032 年）

Rabies Vaccine Market - By Product Type [Baby Hamster Kidney (BHK), Vero Cell Rabies Vaccine], Type (Human, Veterinary), Application (Pre-Exposure Prophylaxis, Post Exposure Prophylaxis), Distribution Channel, Global Forecast (2024 - 2032)

出版日期: 2024年06月13日 | 出版商:

Global Market Insights Inc. | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在疫苗技術進步和醫療基礎設施擴張的推動下，狂犬病疫苗市場規模預計 2024 年至 2032 年複合年成長率將達到 4.5%。疫苗研究的不斷發展正在催生更有效、更容易接種的疫苗，以增強對狂犬病的保護。

對醫療基礎設施的日益關注正在改善疫苗的分發和可及性，特別是在狂犬病較為流行的地區。此外，改進疫苗配方和增加全球供應的不斷努力將推動市場成長。例如，2022年8月，卡迪拉製藥公司推出了世界上第一個針對狂犬病的新型3劑量疫苗，透過簡化的給藥方案加強狂犬病的預防，標誌著在對抗這種致命疾病的鬥爭中取得了重大進展。

整個市場分為產品類型、類型、應用、配銷通路和區域。

就類型而言，在改善動物健康和加強疾病控制的推動下，狂犬病疫苗市場的獸醫部分可能會在 2032 年顯著成長。持續的進步正在為寵物和牲畜提供更有效、更持久的疫苗鋪平道路，以提供更好的狂犬病保護。改良的獸用疫苗可以防止狂犬病從動物傳播給人類並控制疫情。

從配銷通路來看，由於消費者對讓寵物主人和獸醫更容易獲得狂犬病疫苗的需求不斷成長，在線藥房領域的狂犬病疫苗行業價值預計將在 2024 年至 2032 年期間上升。這一轉變使得能夠更輕鬆地採購疫苗以供立即使用和管理狂犬病預防方案。線上平台也致力於簡化訂購流程，並確保疫苗在運輸過程中得到適當的儲存和處理。

從區域來看，在狂犬病發病率上升以及意識和預防計劃不斷增強的推動下，亞太地區狂犬病疫苗市場規模預計將在 2024 年至 2032 年間呈現強勁成長。衛生組織和政府正在促進狂犬病疫苗接種並提高公眾對預防策略的了解。此外，加強預防措施和疫苗接種覆蓋率正在控制狂犬病疫情並降低發病率，從而促進了區域產業的成長。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Bavarian Nordic A/S
Bharat Biotech International Limited
Bio-Manguinhos/Fiocruz
Cadila Pharmaceuticals
China National Biotec Group Co.
Elanco Animal Health Incorporated
GSK plc.
Indian Immunologicals Ltd.
Liaoning Chengda Biological
Merck & Co., Inc.
Novartis AG
Sanofi SA
Serum Institute of India Pvt. Ltd
Virbac
Zoetis Inc.

簡介目錄

Product Code: 9865

Rabies Vaccine Market size is projected to record 4.5% CAGR from 2024 to 2032, driven by advancements in vaccine technologies and the expansion of healthcare infrastructure. Ongoing developments in vaccine research are leading to more effective and easier-to-administer vaccines for enhancing protection against rabies.

The surging focus on healthcare infrastructure is improving vaccine distribution and accessibility, especially in regions where rabies is more prevalent. Moreover, the growing efforts on refining vaccine formulations and increasing global availability will drive the market growth. For instance, in August 2022, Cadila Pharma launched the world's first novel 3-dose vaccine against rabies to enhance rabies prevention with a streamlined dosing schedule for marking a significant advancement in the fight against this deadly disease.

The overall market is segregated into product type, type, application, distribution channel, and region.

In terms of type, the veterinary segment in the rabies vaccine market may experience significant growth by 2032, propelled by increasing adoption to improve animal health and enhance disease control. Ongoing advancements are making way for more effective and longer-lasting vaccines for pets and livestock to provide better protection against rabies. Improved veterinary vaccines are preventing rabies transmission from animals to humans as well as in controlling outbreaks.

By distribution channel, the rabies vaccine industry value from the online pharmacy segment is projected to rise from 2024 to 2032, driven by increasing consumer demand for making rabies vaccine more accessible to pet owners and veterinarians. This shift is enabling easier procurement of vaccines for immediate use and for managing rabies prevention protocols. Online platforms are also working on streamlining the ordering process and ensuring proper storage and handling of the vaccines during shipping.

Regionally, the Asia Pacific rabies vaccine market size is projected to exhibit robust growth between 2024 and 2032, fueled by the rising incidences of rabies and the increasing awareness and prevention programs. Health organizations and governments are promoting rabies vaccination and enhancing public knowledge about prevention strategies. Moreover, enhanced preventive measures and vaccination coverage are controlling rabies outbreaks and reducing incidence rates, adding to the regional industry growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of rabies
  - 3.2.1.2 Technological advancements in vaccine production
  - 3.2.1.3 Growing pet population
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of vaccines
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
3.6 Pipeline analysis
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Baby hamster kidney (BHK)
5.3 Purified chick embryo cell rabies vaccine
5.4 Vero cell rabies vaccine
5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Human
6.3 Veterinary

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pre exposure prophylaxis
7.3 Post exposure prophylaxis

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa